Blockage of glucocorticoid, but not mineralocorticoid receptors prevents the persistent increase in circulating basal corticosterone concentrations following stress in the rat.

Exposure to a single session of intense inescapable stressors results in elevations of plasma corticosterone levels selective to the trough of the circadian rhythm that last for several days after stressor cessation. In the present study, we examined whether this stress-induced alteration in the regulation of the circadian trough is dependent upon glucocorticoid and/or mineralocorticoid receptor activation during stress. Pre-treatment with the mineralocorticoid receptor (MR) antagonist, spironolactone (RU-28318; 50 mg/kg, s.c.), and/or the glucocorticoid receptor (GR) antagonist, mifepristone (RU-38486; 50 mg/kg, s.c.) 1 h before inescapable stress (40, 2.0-mA tail-shocks delivered over a 1 h period) had no effect on the acute plasma corticosterone response to inescapable stress. Treatment with the MR antagonist alone did not affect the appearance of basal corticosterone elevations in stressed rats. However, the elevated trough plasma corticosterone levels were no longer evident in rats treated previously with the GR antagonist either alone or in combination with the MR antagonist. GR activation during stressor exposure appears to be necessary for the development of subsequent basal corticosterone elevations.

Pharmacological suppression of corticosterone secretion in response to a physical stressor does not prevent the delayed persistent increase in circulating basal corticosterone concentration.

Elevated basal plasma corticosterone concentrations have been observed for several days after the cessation of severe stress. In the present study, we examined whether or not the acute plasma corticosterone response to stress is necessary to elicit increased basal plasma corticosterone concentrations the following day. Pretreatment with metyrapone (100 m a g , intraperitoneal)1 h before inescapable stress (40 2mA tail shocks delivered over a 1-h period) (IS)blocked the acute plasma corticosterone response to IS. However, elevated basal plasma corticosterone concentrations still emerged the next day. These results suggest that the corticosterone response to stress, and its attendant feedback, are not necessary to produce persistent hypothalamic-pituitary-adrenal axis (HPAA) activation.

Arachidonylethanolamide (AEA) activation of FOS proto-oncogene protein immunoreactivity in the rat brain.

It is thought that the physiological actions of endogenous cannabinoid arachidonylethanolamide (AEA), as well as exogenous cannabinoids such as Delta9-tetrahydrocannabinol (THC), are mediated by two subtypes of cannabinoid receptors, CB1 and CB2, which have recently been characterized. Injection of AEA leads to alterations in motor behavior and endocrine function. While these phenomena have been well characterized, the neuronal substrate of AEA's actions remains undetermined. In this study, FOS immunoreactivity (FOSir) was used to map rat brain nuclei that are responsive to a single intracerebroventricular injection of AEA. The results showed that FOSir was induced in several nuclei including the bed nucleus of the stria terminalis (BNST), paraventricular nucleus of the hypothalamus (PVN), central nucleus of the amygdala (Ce), periaqueductal gray area (PAG), dentate gyrus in the hippocampus (Dg), paraventricular nucleus of the thalamus (PVA), median preoptic nucleus (MnPO), periventricular nucleus (Pe), caudate putamen (CPU) and the ependymal lining of the ventricles. The pattern of activation identified correlates, in part, with the distribution of CB receptors. At the same time, a new subset of nuclei, without demonstrable CB receptors, have been shown to respond to an AEA challenge. Activation of these nuclei is consistent with the physiological effects of AEA. These findings provide valuable information on the response to AEA at the level of neuronal activation and provide the basis for a broader understanding of the possible role of CB receptors in the modulation of motor and endocrine function associated with the use of exogenous cannabinoids, such as marijuana.

Effects of the circadian rhythm of corticosteroids on leukocyte-endothelium interactions in the AM and PM.

Circadian rhythms are responsible for a number of key cycles within the body. In vivo microscopy was used to investigate the hypothesis that the circadian rhythm of corticosterone in rats produces different leukocyte-endothelium interactions throughout the day. The data indicate that corticosterone levels range from 12 ng/ml in the AM to 260 ng/ml in the PM. In contrast, the number of circulating polymorphonuclear leukocytes (PMNs) yields peak values in the AM (630 PMNs/microl) and trough values in the PM (262 PMNs/microl). During surgical stress there is a significant increase in the number of circulating PMNs in the PM but little change in the AM. Furthermore, there is significantly greater leukocyte-endothelium adhesion in the PM (5.2 cells/100 microm) than in the AM (2.9 cells/100 microm). Addition of the chemoattractant FMLP increased adhesion 125% in the AM but only 62% in PM. Both exogenous glucocorticoid supplementation for 2 weeks and bilateral adrenalectomy abolished the circadian rhythms of circulating PMNs, the number of sticking white blood cells and the initial stages of an acute inflammatory response. These findings suggest that the circadian rhythm of corticosterone alters leukocyte-endothelium interactions throughout the day.

Chronic treatment with morphine and ethanol, but not cocaine, attenuates IL-1 beta activation of FOS expression in the rat hypothalamic paraventricular nucleus.

Interleukin-1 beta (IL-1 beta) is a key mediator of immunological and pathological responses to stress, injury and disease and it has been suggested to have profound effects on neuroendocrine-immune functions. We have shown that central treatment with IL-I beta induces the expression of FOS proto-oncogene protein immunoreactivity (FOS-IR) in several hypothalamic nuclei including the paraventricular nucleus (PVN). Since FOS expression has been used as an anatomical marker of neuronal function, these results suggested that the involvement of IL-1 beta in the neuro-endocrine-immune axis may be mediated through the PVN. Treatment with several substances of abuse has been shown to modify immune function in vivo and in vitro. In this study, we compared the effects of morphine, ethanol and cocaine on IL-1 beta induction of FOS-IR in the rat hypothalamus. Acute treatment with morphine or ethanol induced FOS-IR in several nuclei including the PVN. Cocaine, which induced FOS-IR in the Caudate-Putamen (CPU), nucleus Accumbens (nAcc) and Locus Coeruleus (LC), however, did not induce FOS-IR in the PVN. Chronic treatment with morphine desensitized FOS responsiveness to morphine and IL-1 beta in the PVN since FOS-IR was no longer induced by IL-1 beta or morphine in the PVN after this treatment. Similarly, chronic ethanol treatment desensitized FOS responsiveness to ethanol and to IL-1 beta in the PVN. By contrast, chronic cocaine did not affect FOS responsiveness to IL-1 beta in the PVN even though the treatment was able to desensitize the FOS responsiveness to acute cocaine in the CPU, nAcc, and LC. These results suggest that the PVN may be a site where actions of IL-1 beta converge with those of morphine and ethanol, but not cocaine, to modulate neuro-endocrine-immune functions.

Conformational studies of N-Tyr-MIF-1 in aqueous solution by 1H nuclear magnetic resonance spectroscopy.

N-Tyr-MIF-1 (Tyr-Pro-Leu-Gly-NH2) is an endogenous brain peptide with multiple effects on animal behavior. However, there have been no studies on the conformation of this tetrapeptide. In this report, we studied the conformation of N-Tyr-MIF-1 in aqueous solution by conventional one-dimensional and two-dimensional (COSY and NOESY) 1H nuclear magnetic resonance spectroscopy at 300 MHz. A complete set of assignments for the resolved resonances and approximate assignments for the overlapping resonances were made. The results demonstrate that N-Tyr-MIF-1 is in slow exchange between two conformers, most likely determined by the cis and trans states of the proline residue. The minor conformation represents 30 +/- 3% of the population over the temperature range from 3 degrees to 73 degrees. In the major conformation, the tyrosine aromatic ring appears to be close enough to interact directly with the proline pyrrolidine ring, as indicated by a strong temperature dependence of the proline C beta H, C delta H and C delta H' chemical shifts. In contrast, this interaction of the tyrosine and proline rings is not present in the minor conformation.

Circadian variation in response to CRF-41 and AVP.

The diurnal response to ovine corticotropin-releasing factor (CRF-41), arginine vasopressin (AVP), and adrenocorticotropic hormone (ACTH) was studied in rats in which the endogenous release of CRF was blocked by chlorpromazine, morphine sulfate, and pentobarbital sodium. This procedure resulted in a markedly attenuated circadian rhythm at base-line levels of plasma corticosterone and ACTH. Decreased pituitary responsiveness to CRF-41 and AVP at 0400 compared with 1600 was observed. The plasma corticosterone response 30 min after intravenous injection of ovine CRF-41 (0.1 microgram/kg) or AVP (5.0 micrograms/kg) remained nearly constant over the major portion of the 24-h light-dark cycle. However, in the early morning (0400), 2 h before lights on, there was an approximately threefold decrease in response. The time of this decrease in response coincided with the normal decline in the concentrations of plasma corticosterone and ACTH. Rats exposed to constant darkness for 10 days continued to show a significantly greater response to CRF or AVP at 1600 than at 0400. In contrast, rats exposed to constant light for 10 days failed to demonstrate a differential response to CRF or AVP at different times of the day. These results demonstrate that there is a diurnal rhythm in pituitary response to CRF and AVP.

Constant light and dark affect the circadian rhythm of the hypothalamic-pituitary-adrenal axis.

The effect of constant light and constant dark on the circadian rhythm of the concentrations of hypothalamic corticotropin-releasing-factor-like immunoreactivity (CRF-LI), plasma ACTH, and corticosterone was investigated. Groups of rats were maintained under normal light-dark, constant light, or constant dark conditions for 10 days. Rats were then killed over a 24-hour time period and hypothalamic CRF-LI, plasma ACTH, and corticosterone concentrations were determined by radioimmunoassay. Under normal light-dark conditions, troughs in hypothalamic CRF-LI concentrations coincided with peaks in plasma ACTH and corticosterone concentrations. In rats housed under constant dark conditions for 10 days, higher hypothalamic CRF-LI concentrations were detected at 20.00, 24.00 and 04.00 h than at 08.00, 12.00 and 16.00 h. These relatively high hypothalamic CRF-LI concentrations coincided with relatively low plasma ACTH concentrations. The amplitude of plasma ACTH concentrations was markedly attenuated compared to levels of rats housed under normal light-dark conditions. The rats exposed to constant dark continued to demonstrate higher plasma corticosterone concentrations post meridiem than ante meridiem. The peak in plasma corticosterone coincided with the peak in plasma ACTH concentrations; however, the amplitude was normal. In rats maintained in constant light for 10 days, a decrease in hypothalamic CRF-LI concentrations at 20.00 h coincided with a peak in plasma ACTH. The peak in plasma ACTH concentrations was not associated with a peak in plasma corticosterone concentrations. The rhythm of plasma corticosterone concentrations was dramatically attenuated and phase-shifted. Together, these findings indicate that alterations of normal light-dark conditions result in changes in the circadian variation in hypothalamic CRF-LI, plasma ACTH, and corticosterone concentrations.(ABSTRACT TRUNCATED AT 250 WORDS)

Cocaine induced secretion of ACTH, beta-endorphin, and corticosterone.

The effect of intraperitoneal administration of cocaine on the concentrations of hypothalamic corticotropin releasing factor like-immunoreactivity (CRF-LI), plasma ACTH, beta-endorphin, and corticosterone was investigated. Groups of rats were injected with 20 mg/kg cocaine HCI or 0.9% NaCl and then killed 0, 10, 20, 30 or 60 minutes later. Hypothalamic CRF-LI, plasma ACTH, beta-endorphin, and corticosterone concentrations were determined by radioimmunoassay. A significant increase in plasma ACTH, beta-endorphin, and corticosterone concentrations was observed after cocaine administration. In contrast, cocaine had no significant effect on hypothalamic CRF-LI concentrations. Intravenous administration of 0.5 and 2.0 mg/kg cocaine to rats in which the endogenous release of CRF was blocked by chlorpromazine, morphine, and pentobarbital elicited a significant increase in plasma corticosterone concentrations. These results demonstrate that cocaine induces the release of ACTH, beta-endorphin, and corticosterone and suggest that this response is mediated at the pituitary level.

Stress mediated changes in hypothalamic corticotropin releasing factor-like immunoreactivity.

Hypothalamic corticotropin releasing factor-like immunoreactivity (CRF-LI), plasma ACTH and corticosterone levels were measured by radioimmunoassay over a two hour period of restraint stress. The results of this study demonstrate a significant decrease in hypothalamic CRF-LI levels 15 and 30 minutes after the start of restraint stress which is followed by a significant increase at 60 minutes that is abolished by cycloheximide pretreatment. Plasma ACTH and corticosterone levels were significantly elevated after 15, 30, 60, 90, and 120 minutes of restraint stress. These results are consistent with a release of CRF from the hypothalamus during stress. The cycloheximide-sensitive increase in hypothalamic CRF-LI indicates that synthesis of CRF-41 occurs during prolonged stress. These results suggest that the response of an organism to exposure to a long-term, high intensity stress involves both the release and synthesis of CRF-41.

Circadian rhythm of corticotropin releasing factor-like immunoreactivity in rat hypothalamus.

Levels of hypothalamic corticotropin releasing factor-like immunoreactivity (CRF-LI) were measured by radioimmunoassay (RIA) over a 24 hour light-dark cycle and found to exhibit two peaks. One peak was detected at 1100 hr and a secondary smaller peak was found at 2000 hr. The trough between the two peaks was detected at 1700 hr which coincided with the peak in plasma corticosterone levels. The results are consistent with a decreased level of hypothalamic CRF-LI at 1700 hr reflecting an increased release of peptide followed successively by the release of ACTH and corticosterone.

In vivo potentiation of corticotropin releasing factor activity by vasopressin analogues.

The ability of the neurohypophyseal hormones and related synthetic peptides to potentiate the action of synthetic ovine corticotropin releasing factor (CRF-41) was examined using male rats whose endogenous CRF release was blocked with chlorpromazine, morphine and nembutal. CRF potency was clearly related to the pressor activity of the analogues. However, the threshold dose for eliciting a significant corticosterone response with the neurohypophyseal hormones was greater than with CRF-41. When arginine vasopressin (AVP) was coadministered with CRF-41 at subthreshold doses of both peptides, a significant corticosterone response was observed. When the neurohypophyseal hormone analogues were compared with regard to intrinsic CRF bioactivity, it was observed that an L-basic residue in sequence position 8 is necessary for high intrinsic activity. With one exception, l-Deamino-(9-D-Ala) arginine vasopressin, the ability to potentiate the effect of CRF-41 was related to the intrinsic CRF potency of the analogues. These results support previous reports of in vitro potentiation of CRF-41 by AVP and point out the complexity of CRF-neurohypophyseal hormone interaction in vivo.

Production of antiserum to CRF associated with adrenal atrophy in a rabbit.

Corticotropin releasing factor (CRF) was recently isolated from ovine hypothalami by its ability to stimulate adrenocorticotropin (ACTH) and beta-endorphin release from dispersed rat pituitary cells. Intramuscular injection of synthetic ovine CRF conjugated to bovine thyroglobulin with 1-ethyl-3(3-dimethylaminopropyl) carbodiimide and emulsified with Freund's complete adjuvant into a random bred New Zealand white rabbit resulted in antiserum production to CRF associated with adrenal atrophy. A decrease in the level of plasma corticosteroids was associated with an increase in mean total binding of 125I-N-Tyr-CRF. Upon sacrifice, a decrease in pituitary content of ACTH and a decrease in adrenal weight and content of corticosteroids was observed in the rabbit producing antiserum to CRF. Adrenal atrophy was histologically verified with an observed decrease in the adrenal cortical zone not reflected in the zona glomerulosa. Individual cells were relatively larger either with more abundant pale cytoplasm or with distinctly vacuolated cytoplasm. The results presented here are consistent with a physiologically necessary role for this CRF or peptides with similar structures in the hypothalamic-pituitary-adrenal axis.

Distribution of CRF-like immunoreactivity in the rabbit.

CRF-like immunoreactivity was measured by radioimmunoassay in the brains and gastroenteropancreatic tract of normal rabbits. It was detected in the brain, with the highest concentration being found in the ventral hypothalamus. The distribution of immunoreactivity was much more limited in the rabbit brain than in the rat brain, with substantial amounts of peptide detected only in areas of close proximity to the hypothalamus, e.g., thalamus, preoptic area, midbrain and amygdala. In addition, the extrahypothalamic immunoreactivity was slightly retarded on Sephadex G-50 chromatography relative to rat CRF-like immunoreactivity and synthetic ovine CRF. No apparent CRF-like immunoreactivity was detected in boiling water extracts of lung, pancreas, duodenum or antrum. These data in conjunction with a previous repeat of void volume immunoreactivity on Sephadex G-50 only in the hypothalamus suggest that CRF is synthesized only in the hypothalamus and is not a member of the class of peptides found throughout the gastroenteropancreatic tract and the central nervous system.

Physiological changes in rat hypothalamic CRF: circadian, stress and steroid suppression.

Hypothalamic CRF-like immunoreactivity was measured in the a.m. and p.m., after systemic dexamethasone administration or after either stress in adult male rats. Measurement of plasma corticosterone levels revealed the expected circadian rhythmicity, suppression after dexamethasone administration and increase after ether stress. The hypothalamic content of CRF-like immunoreactivity was significantly decreased in the p.m. and after dexamethasone administration. However, no change in hypothalamic CRF-like immunoreactivity was observed after ether stress. The results are consistent with an increased release in the p.m. and decreased synthesis of hypothalamic CRF after systemic dexamethasone administration. The observation that there is no change in content of hypothalamic CRF-like immunoreactivity after ether stress could be due to the fact that the animals were stressed by handling. The results show that this immunoreactivity present in the hypothalamus is altered by changes in the hypothalamic-pituitary-adrenal axis and thus suggest that this peptide is a physiologically significant CRF in the rat.

Extrahypothalamic distribution of CRF-like immunoreactivity in the rat brain.

CRF-like immunoreactivity was measured by radioimmunoassay in the brains of normal adult rats and found to be widely distributed in extrahypothalamic areas (e.g., thalamus, amygdala, hippocampus, frontal cerebral cortex, striatum, midbrain, pons-medulla and cerebellum) at levels approximately 10% of the hypothalamus. Sephadex G-50 gel filtration reveals that CRF-like immunoreactivity in the hypothalamus coelutes with synthetic ovine CRF and is also present in the void volume. However, in the extrahypothalamic areas of the rat brain, only CRF-like immunoreactivity that coelutes with synthetic ovine CRF was detected. High performance liquid chromatography revealed equal amounts of immunoreactivity coeluting with CRF and methionine sulfoxide CRF in hypothalamic extracts.

Hypothalamic CRF-like immunoreactivity in the rat after hypophysectomy or adrenalectomy.

Hypothalamic CRF-like immunoreactivity was measured in normal, hypophysectomized or adrenalectomized adult male rats. As expected, adrenalectomy resulted in decreased levels in plasma corticosterone and increased plasma levels of ACTH; hypophysectomy resulted in decreased levels in both corticosterone and ACTH. The hypothalamic content of CRF-like immunoreactivity in animals two weeks post-hypophysectomy or adrenalectomy was approximately seven times greater than that found in intact animals. At one week, post-surgery, small but statistically significant decreases in content of CRF-like immunoreactivity were observed. The results at one week are consistent with removal of feedback effects of ACTH and corticosterone causing increased release of CRF and decreased content. The increase in CRF-like immunoreactivity two weeks post-surgery is probably not related to direct feedback effects on release but may be due to increased synthesis secondary to long term removal of feedback inhibition.

Radioimmunoassay of CRF-like material in rat hypothalamus.

Corticotropin releasing factor (CRF) was recently isolated from ovine hypothalami by its ability to stimulate adrenocorticotropin (ACTH) and beta-endorphin release from dispersed rat pituitary cells. In order to study the physiology of this peptide, we have developed a sensitive and specific radioimmunoassay (RIA) for CRF. Synthetic CRF was conjugated to bovine thyroglobulin and emulsified with complete Freund's adjuvant. A suitable antiserum was obtained which showed no crossreactivity with eight naturally occurring peptides. N-Tyr-CRF was iodinated and used as tracer. With this assay, CRF-like immunoreactivity which coeluted with ovine CRF on Sephadex G50 was detected in rat hypothalami.